Linked Life Data

15126602

Source:http://linkedlifedata.com/resource/pubmed/id/15126602

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2004-5-5
pubmed:abstractText
In recent years, several research subjects have told us that they had bought or intended to buy stock in the companies sponsoring the clinical trials in which they were enrolled. This situation has led us to ask what, if any, are physician-investigators' scientific, ethical, and legal responsibilities concerning research subjects who choose to buy stock in the companies sponsoring the clinical trials in which they are participating. Although the scope of this problem is unknown and is likely to be small, this commentary examines the scientific, ethical, and legal concerns raised by such activities on the part of research subjects enrolled in early phase clinical trials. In addition, this commentary also outlines the basis for our opinion that research subjects involved in an early phase clinical trial should avoid the financial conflicts of interest created by trading stock in the company sponsoring the clinical trial.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1460-2105
pubmed:author
pubmed:issnType
Electronic
pubmed:day
5
pubmed:volume
96
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
656-61
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
pubmed:affiliation
Department of Medicine, Indiana University School of Medicine, the Regenstrief Institute for Health Care Research, and the Indiana University Center for Bioethics, Indianapolis, IN, USA. phelft@iupui.edu
pubmed:publicationType
Journal Article, Review